Fio Spin

🚨Ya sacaron la asistencia al viajero de Assist card MUY BARATA y con doble descuento?🚨 Assist Card Con descuento de hasta 40% off Más 20% extra con código PROMOS20OFF Solo desde acá assistcard.com/ar/b2c/promos-… La asistencia anual para todos los viajes por un año de hasta 30 días queda en 3 cuotas de 79.000$ aprox El cupón se aplica en el último paso.

SOUND ON. You’re hearing the first howl of a dire wolf in over 10,000 years. Meet Romulus and Remus—the world’s first de-extinct animals, born on October 1, 2024. The dire wolf has been extinct for over 10,000 years. These two wolves were brought back from extinction using genetic edits derived from a complete dire wolf genome, meticulously reconstructed by Colossal from ancient DNA found in fossils dating back 11,500 and 72,000 years. This moment marks not only a milestone for us as a company but also a leap forward for science, conservation, and humanity. From the beginning, our goal has been clear: “To revolutionize history and be the first company to use CRISPR technology successfully in the de-extinction of previously lost species.” By achieving this, we continue to push forward our broader mission on—accepting humanity’s duty to restore Earth to a healthier state. But this isn’t just our moment—it’s one for science, our planet, and humankind. All of which we love and are passionate about. Now, close your eyes and listen to that howl once more. Think about what this means for all of us.

anda, ya me ha salido el spotify wrapped

So excited to finally see this idea out in public!! I can’t wait to hear the behind the scene stories and all the changes that happens between the preprint and the final version of a paper. More talks to come, stay tuned!!

Nature rejected her paper for not being original, University of Pennsylvania (her employer) demoted her, and yesterday Katalin Karikó won the Noble Prize in physiology. In mid-2000s, Karikó and her Drew Weismann submitted their paper on mRNA (messenger Ribonucleic Acid) to Nature. Nature desk rejected their paper for being "an incremental contribution" only. The paper was later published in another journal, Immunity. Earlier in her career at the University of Pennsylvania, Karikó was demoted because her applications for grants kept getting rejected. But Karikó persevered and kept on going. In 2013, she joined BioNTech, a German company founded by two scientists, Uğur Şahin and Özlem Türeci. In 2018, BioNTech partnered with Pfizer to develop mRNA vaccines against the influenza virus. When the COVID-19 hit the world, Karikó's research helped Pfizer to produce the first vaccine against the disease. I don't know how the Nature editors who desk rejected Karikó's paper and the Penn administration who demoted her feel about Karikó Nobel Prize. Takeaway: Many academics and scientists worry about getting published in "prestigious" journals. Instead of worrying about prestige, we should try to put our work out as quickly as possible like Karikó did. Once you put your work out without caring about prestige, two good things happen: 1. Your work will lead to newer opportunities. 2. You will start getting feedback from the scholarly community, which you can use to iterate and improve. Here's another interesting Nobel Prize story. Peter Higgs, a British physicist, joined the University of Edinburgh in 1956. By 1964, Higgs has published his groundbreaking work about subatomic particles. After 1964, Higgs published less than 10 papers. When his department would ask him how many papers, he published in a given year, he would reply "None." It happened so often that he stared feeling like an "embarrassment to the department." The University of Edinburgh, however, never fired Higgs because in 1980 he had been nominated for the Nobel Prize. Higgs retired in 1996 and stayed on as an emeritus professor at Edinburg. In 2012, experiments conducted at the CERN laboratory confirmed Higgs work and the existence of Higgs Particle. And in 2013, Higgs was awarded the Noble Prize in physics and the University of Edinburgh got rewarded for being patient.

Google just released ChatGPT's strongest competitor yet - Bard It's free to use and comes with 10X more features. Here are some of the craziest things only Bard can do ( ChatGPT cannot) 🧵

@Micapequi @Alemoroni23 Yo también Michael!

@Alemoroni23 @fiovortex Fioreloooo te extrañamos 💞

@Micapequi @Alemoroni23 Jajajajaja me hacen morir ustedes

@Alemoroni23 Que pasa andas sensible? 🙈

@EstermannMartin Congrats Martincito 👏🏼👏🏼

Out last paper is out! This side project started with an unexpected result that we kept exploring further. Having an undifferentiated supporting cell marker changes everything! I wish I can continue exploring this process in the future!

Check this @iScience_CP #MLKL #extracellularvesicle #glioblastoma @LabSoap @Crci2naClub @Gwennan_AG @c_maghe @TiphaineDouanne @kjacobs7192 @nbidere @An12T @fiovortex @KilianTlt @SRosinska + collaborators @GoetzJacky @HyenneV @BusnelliIgnacio @fmgcavalli cell.com/iscience/fullt…

This is too good 🤣

@ALDZ73 Gracias Lau por la oportunidad ❤️

Gracias infinitas a todos los que participaron del curso !!a todo el lab de Microamiente Tumoral + @fiovortex 🤗...al CIBA, Inst. Posgrado... por hacerlo posible. CIBA, UNNOBA. Junin,Bs. As.

Curso sobre cultivos celulares y cultivos primarios unnoba.edu.ar/curso-sobre-cu…

@fmendiguren Los mejores pintxos del mundo 😍❤️

Quiz para gordos: ¿Qué lugar sagrado está en esa esquina del fondo a la derecha?

Ya esta abierta inscripcion!!

Thank you @AlexisGautreau for putting together this workshop on cancer research @LabSoap looking forward to participate and gather with @JaulinLab @GoetzJacky @ChrisGinestier and more #notontwitter

Thanks @fiovortex we love so much #dulcedeleche #happinessinacake 🇦🇷

This @LabSoap #TwitterBirthday this is how we can celebrate #wecelebrateitall

Read about @Gwennan_AG @labsoap @CrcinaClub @ICO_cancer work on #extracellularvesicle #glioblastoma with @IzonScience izon.com/news/evs-and-g…

Trillet et al. report that the glycoprotein GP130 orchestrates the availability of the G protein–coupled receptor for apelin APLNR at the plasma membrane of #glioblastoma stem-like cells, thereby modulating APLN signaling toward self-renewal bit.ly/3zlLvvz